Lupin bets big on inhalation segment, plans to enter Chinese market

Lupin's portfolio and pipeline addresses 70 per cent of the entire market

The $2 billion pharma giant, Lupin, has been slowly building a strong portfolio of inhalation products to tap the complex generics respiratory products market globally. The firm is looking for manufacturing partners to enter the Chinese market with a handful of respiratory products that it has either commercialised in other regulated markets or is in the pipeline.

Vinita Gupta, chief executive officer (CEO), Lupin, said it has been working on building a complex generics respiratory portfolio with focus on inhalation products for the last five-six years. The firm has been utilising around 10 per cent of its research and development (R&D)